Andrew H Lipsky, MD

Andrew H Lipsky, MD, is an assistant professor of Medicine at the Columbia University Medical Center.

Articles by Andrew H Lipsky, MD

Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD

January 31st 2026

Andrew Lipsky, MD, discusses data with pirtobrutinib in relapsed/refractory CLL and the effect of its FDA approval on sequencing decisions for this disease.

Latest Updated Articles

Andrew H Lipsky, MD

Articles by Andrew H Lipsky, MD

Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer

Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma